Tamoxifen, a selective estrogen receptor (ER) modulator (SERM), remains a frontline clinical therapy for patients with ERα-positive breast cancer. However, the relatively rapid development of resistance to this drug in the metastatic setting remains an impediment to a durable response. Although drug resistance likely arises by many different mechanisms, the consensus is that most of the implicated pathways facilitate Wright et al (2014) 3 Implications: These findings reveal the transcriptional interplay between FOXA1 and ERα in controlling AGR2 during the transition from therapy-sensitive to -resistant breast cancer and implicate AGR2 as a relevant therapeutic target.
INTRODUCTION
Approximately 40,000 women die from breast cancer each year, making it the leading cause of early mortality in women (1) . Most breast cancers are estrogen receptor alpha (ER) positive and recognize estrogens as mitogens. Therefore, not surprisingly, strategies that interfere with ER action have emerged as frontline therapies for the treatment and prevention of breast cancer. Specifically, ER can be effectively targeted at the level of (a) receptor activity, using selective estrogen receptor modulators (SERMs), such as tamoxifen, and selective estrogen receptor degraders (SERDs) or (b) ligand availability, using aromatase (cyp19) inhibitors. However, close to 60% of ER-positive tumors exhibit intrinsic resistance or rapidly acquire resistance to endocrine interventions (especially in the metastatic setting), requiring the subsequent use of largely ineffective cytotoxic therapies (2) (3) (4) . Unfortunately, it has been difficult to predict de novo resistance to endocrine therapy and/or assess the likelihood of early relapse.
Some progress in this regard was made with the development of the HoxB13/IL17RB gene predictor (5) , although clinically this test has not been widely used and its utility remains unclear. Thus, there is an unmet medical need to define the fundamental processes underlying endocrine resistance with a view to developing mechanism based diagnostic tests to assess likely drug responses and to identify new approaches to mitigate the impact of resistance. activate transcription (4, 6) . Additionally, several recent studies have described the identification of proto-oncogenes whose expression and/or activities are positively upregulated by endocrine manipulation and which alter tamoxifen pharmacology. One such proto-oncogene, the secreted protein AGR2 (anterior gradient homology 2), has been shown to exhibit oncogenic activities in several malignancies including breast, ovarian, pancreatic and prostate cancer (7) (8) (9) (10) (11) . Further, this protein is overexpressed in primary tumors and in cellular models of breast cancer (12) (13) (14) . Although ER+ breast cancers, in general, exhibit a low histological grade, the expression of AGR2 in this tumor subtype is associated with a poorer outcome (8, 12, 15) . Furthermore, in primary ER+ tamoxifen treated breast cancers, AGR2 overexpression is linked to tamoxifen treatment failure (8) . Recently it was demonstrated that AGR2 is a direct ER target gene in MCF7 cells. More importantly, however, it was observed that tamoxifen induced the expression of this gene similar to the ER agonist estradiol (8) . Thus, it is possible that although tamoxifen is an effective antagonist on most ER-responsive genes, its ability to activate AGR2 expression may limit its therapeutic response (7, 8, 16 ).
In addition to serving as a marker of resistance to endocrine therapy, it is likely that AGR2 itself contributes in a significant manner to tumor biology. However, there is minimal information as to how AGR2 manifests its oncogenic activities. It has been demonstrated that AGR2 has the structural features of a protein disulfide isomerase although a potential substrate(s) for these activities has yet to be identified. Further, it is not known if the isomerase activity of this protein is required for its oncogenic functions. Given that it is a secreted protein, it is not surprising that some have considered the possibility that AGR2 may be involved in the folding of the extracellular domains of proteins that influence cell growth and survival (17, 18) . Although it has also been shown that the secreted AGR2 protein influences gene expression, it is unclear if this is accomplished as a consequence of its ability to (a) modulate the activity of some cell surface protein, (b) bind to and activate a specific "AGR2" receptor or (c) function as a direct modulator of an intracellular signaling pathway. Regardless, considering our interest in defining the molecular pharmacology of tamoxifen, we embarked on a study to evaluate the impact of AGR2 expression on the transition of breast cancer cells from a tamoxifen sensitive to a tamoxifen resistant state and to define the mechanisms by which tamoxifen manifests agonist activity on the AGR2 promoter. It was anticipated that this study would be informative with respect to the specific processes that enable the ER:tamoxifen complex to activate AGR2 expression and may highlight the mechanisms underlying the activity of this and other SERMs. For experiments, cells were plated in media lacking phenol red with 8% charcoal stripped FBS (CFS; Gemini). Unless otherwise indicated, cells were plated for 48 hours and then treated for 24 hours with 17β-estradiol (E2; Sigma), 4-hydroxytamoxifen (4OHT; Sigma) or ICI182,780 (ICI; Tocris) as indicated and RNA or protein harvested.
Plasmids.
The pLenti CMV puro Gal4-DBD (control) and pLenti CMV puro AGR2 plasmids were generated by subcloning Gal4-DBD and AGR2 cDNA into pENTR1a (Invitrogen) and recombining into pLenti CMV puro DEST (Invitrogen).
Gene silencing and overexpression.
Small interfering RNA (siRNA) were used to transiently silent ERα (Invitrogen), AGR2 six-well plate and transfected using Dharmafect IV (Dharmacon) for 48-72 hours, unless otherwise specified.
pLenti CMV puro Gal4-DBD and pLenti CMV puro AGR2 plasmids were cotransfected (Fugene, Roche Applied Science) with the vsvg, gag-pol and rev packaging vectors into 293FT cells. The viral supernatants were filtered and supplemented with 8ug/mL polybrene before infecting MCF7 cells for two serial 24-hour periods. Cells were then selected with 1ug/mL puromycin yielding the MCF7 Gal4 and MCF7 AGR2 cell lines.
RNA preparation and qRT-PCR analyses.
Total RNA was prepared using the Aurum Total RNA Mini Kit (BioRad). cDNA was synthesized from 0.5ug total RNA using the BioRad iScript cDNA Synthesis Kit. 
Immunoblotting.
Cells were lysed in whole cell extract buffer containing 100mM Tris-HCl pH8.0, 2mM EDTA, 0.02% SDS, 0.5% Nonidet P-40 and 150mM NaCl and 1x protease inhibitors Bioinformatics Analyses.
Forest Plot -
To query the prognostic significance of our 4OHT induced genes, we assembled a metaset of breast cancer patients from 25 publicly available datasets, which included 4885 patients. The Affymetrix microarray data (HGU133plus2 and HGU133A) was downloaded from GEO, normalized with fRMA (32) and batch corrected using the COMBAT algorithm within R yielding only the probe sets common between the two platforms. Clinical data was also aggregated from GEO and duplicate patient samples were removed. Each tumor was then classified into tumor subtypes using the PAM50 
RESULTS

The ER-target gene AGR2 is constitutively expressed in models of tamoxifen resistant ER positive breast cancer
Previously, we identified a set of genes whose expression in MCF7 cells was positively upregulated by 4-hydroxytamoxifen (4OHT) and whose induction by other SERMs reflected the relative agonist activity of the compound tested (19) . Analysis of the prognostic significance of these genes in luminal A cancers revealed that the expression of PTGES and AGR2 were among the most significantly associated with poor outcome ( Figure 1A ). Since previous clinical data suggests that PTGES has no major effect on breast cancer susceptibility or survival among those with invasive breast cancer (20) , we chose to focus on AGR2. AGR2 is a proto-oncogene whose expression is shown to be induced by 17β-estradiol (E2) in several cancers of epithelial origin (7, 8, 16) . Further, there is considerable interest in using AGR2 as a potential biomarker of drug resistance in breast cancer (17, 18) . Given these data, we decided to evaluate the extent to which AGR2 contributes to the pathobiology of ER-positive breast cancer and influences the response of these cancers to tamoxifen.
We have developed a cellular model of tamoxifen resistance (TamR) from an MCF7 xenograft tumor continually treated with tamoxifen in vivo until the onset of resistance.
In contrast to TamR models developed by continuously treating cells with tamoxifen in vitro (21, 22) 
Recently, it has been reported that AGR2 is a proto-oncogene that regulates mammary epithelial cell proliferation (24) and that elevated expression of this protein is associated with increased cell proliferation and migration in breast cancer cells (7, 8) . However, a role for AGR2 in the pathology of tamoxifen resistant breast cancer has not been defined. Therefore, we performed a comparative analysis of the impact of siRNAmediated knockdown of AGR2 expression on the growth of MCF7 and TamR cells. The results of this study, performed using two different siRNAs, revealed that AGR2 was required for the growth and survival of both tam sensitive MCF7 and tam resistant TamR cell lines (Figure 2A, Supplementary Figure 2) .
One of the characteristics of the TamR cells, in comparison to MCF7 cells, is that they have a high migratory potential when assayed in vitro. Given that others have shown that AGR2 influences cell migration (7, 8) , we evaluated the effect of AGR2 knockdown on cell migration. As shown in Figure 2B , E2 treatment increased the migration of TamR cells and this effect was ablated upon siRNA mediated knockdown of AGR2 expression.
To confirm the role of AGR2 in cell migration, we used a lentiviral-based approach to overexpress AGR2 in MCF7 cells. It has been established that AGR2 is a secreted protein and we were able to demonstrate that the recombinant AGR2 produced in the cell lines we developed was indeed secreted ( Figure 2C 
TamR cells ( Figure 2C ). Taken together, these data indicate that intracellular AGR2 promotes cellular proliferation while secreted AGR2 promotes migration, and that its constitutive expression in models of endocrine resistant cancer is likely to be important in disease pathogenesis.
AGR2 overexpression enhances E2 stimulated growth of ER-dependent xenografts in vivo
We next undertook a series of studies to assess the impact of AGR2 overexpression on tumor growth and tamoxifen response in MCF7-cell derived xenografts. To this end, expressing counterparts ( Figure 3A) . It was also observed that when compared to Gal4, AGR2 expression reduced the efficacy of tamoxifen, although the differences between these groups did not reach statistical significance ( Figure 3A) . The effect of AGR2 on tamoxifen pharmacology was more apparent when the data were presented as time to event (tumors >400mm 3 ) ( Figure 3B ). Upon E2 withdrawal alone, no changes were observed between the Gal4 and AGR2 expressing tumors ( Figure 3C ).
However, it was observed that upon E2 withdrawal, the efficacy of tamoxifen was reduced in AGR2 expressing tumors ( Figure 3C ). Taken together, these data indicate that AGR2 impacts the pathobiology and pharmacology of tumors in mice, although its expression alone is not sufficient to confer tamoxifen resistance in the selected models.
AGR2 expression in tamoxifen resistant breast cancer cells loses its dependence on ER
As described above, we determined that while ICI reduces basal and E2-induced AGR2 and TSPAN13 map to the same locus on chromosome 7. We therefore elected to focus our studies on FOXA1 as (a) it has been shown to function as a pioneer factor for ER on many genes, (b) its expression has been associated with tamoxifen resistance in published studies (25, 26) , (c) we and others (27, 28) 
DISCUSSION
Recently, there has been renewed interest in identifying specific genes that are causally linked to the development of resistance to endocrine therapy in breast cancer and the identification of pathways downstream of ERα that may be amenable to targeted therapeutic intervention in this disease. It is within this context that we undertook a study to probe the role of the proto-oncogene AGR2 in tamoxifen pharmacology in breast cancer. In general, ER+ breast tumors are associated with a more favorable prognosis, considered to be less aggressive, and are likely to respond to SERMs such as tamoxifen. However, ER+ AGR2 overexpressing breast tumors treated with tamoxifen are significantly more aggressive and exhibit a poor prognosis (8, 12, 15) .
Consequently, ER+ AGR2 overexpressing tumors are considered to be intrinsically resistant to tamoxifen and/or are poised to develop resistance to endocrine therapy. It was of significance, therefore, that we observed that heterologous expression of AGR2 increased the growth of MCF7-cell derived xenografts and altered their response to tamoxifen. These findings suggest a causal role for AGR2 in the processes of pathological importance in breast cancer and highlight its likely role in the development of tamoxifen resistance.
Our interest in AGR2 originated from the observation that it was an estrogen responsive gene that was overexpressed in breast cancer. However, it has since been found to be expressed in many cancer types including pancreatic, ovarian and esophageal carcinomas (10, 11, 29) , where it plays critical roles in cell migration, growth factor secretion and proliferation. Likewise, in breast cancer, we and others have shown that 
AGR2 expression promotes cell survival, proliferation and metastasis (7, 8) . Of particular importance was the finding that elevated expression of AGR2 in the index biopsy of primary tumors is associated with early progression in patients treated with tamoxifen (8), a result that has led to the suggestion that this protein may contribute to tamoxifen resistance. These findings heightened interest in using AGR2 as a potential biomarker of resistance to endocrine therapy in ER+ breast cancers. However, until this current study, the mechanisms by which AGR2 influences the development of tamoxifen resistance had yet to be explored. In this study, it was shown that AGR2 was absolutely required for the growth of both tamoxifen sensitive and tamoxifen resistant breast cancer cells in vitro. Further, it was demonstrated that heterologous overexpression of AGR2 enhanced the estrogen dependent growth of MCF-7 derived tumor xenografts and that the resultant tumors were less sensitive to the antiestrogenic actions of tamoxifen. These findings also highlight the importance of the observation that AGR2 expression was elevated in a validated model of tamoxifen resistant breast cancer and that its expression loses its dependence on ER.
Previously, we determined that the induction of AGR2 expression by tamoxifen in MCF-7 cells is a direct, ER dependent, transcriptional response. However, we are as yet unable to reconcile these findings with those of others in the same cell line, which indicates that the induction of AGR2 gene expression in response to tamoxifen occurs as a result of the non-genomic activity of ER on signaling molecules in an AKT dependent manner (30) . This encouraged us to undertake a comparative bioinformatics analysis to define proteins and/or processes that may be involved in AGR2 expression 
in this context. The results of this analysis informed a series of genetic studies that indicated that FOXA1 was required for AGR2 expression in the assayed breast cancer cell types. However, the observation that FOXA1 expression levels did not change as cells progressed from a tamoxifen sensitive to a tamoxifen resistant state suggested that increased FOXA1 activity was a key contributor to the resistance phenotype.
Identification of the proteins and/or processes that impact FOXA1 activity is thus a major focus of our efforts in this area.
In both MCF7 and TamR cellular models, we found that knockdown of AGR2 expression resulted in a quantitative downregulation of ER gene transcription and a loss of the receptor protein. A similar conclusion was arrived at by others studying ER expression in T47D and ZR751 breast cancer cell models (7) . However, the mechanisms by which this occurs are elusive and resolution of this issue awaits a more comprehensive analysis of the biochemical activities and potential targets of AGR2.
Regardless, it appears that ER can regulate AGR2 expression and that this in turns upregulates ER expression. Interestingly, although AGR2 expression in tamoxifen resistant cells no longer requires ER, the sustained expression of ER still requires AGR2. Thus, the ER/AGR2 step of the normal ER/AGR2/ER regulatory loop is cancer. The importance of FOXA1 in breast cancer physiology has been established, although in and of itself is not likely to be a druggable target. On the other hand, since it is a secreted protein, AGR2 may be a viable target using a neutralizing antibody approach. Such an intervention may have utility as an alternative to, or in conjunction with SERMs or SERDs, as a treatment for ER-positive cancers. It also remains to be determined how, with no change in expression, FOXA1 is able to sustain the expression of AGR2 in a manner that no longer requires ER. Indeed, it is inferred from our work that the pathways that impinge on FOXA1 to facilitate its ER independent activity are also likely to be useful targets for the treatment of breast cancer. Taken together, this study shows that the FOXA1/ER/AGR2 signaling axis is a viable option for therapeutic intervention and that the specific targeting of the proto-oncogene AGR2 is likely to provide an option for the future therapeutic treatment of breast cancer. 
